Search
Eltrombopag
go.drugbank.com/drugs/DB06210ApprovedInvestigationalITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. … Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: REVOLADE ® TABLETAS 50 MG, REVOLADE® TABLETAS 25 MGLetermovir
go.drugbank.com/drugs/DB12070ApprovedInvestigational[L1021] It is the first of a new class of CMV anti-infectives called DNA terminase complex inhibitors.[A31290] Letermovir has recieved both priority and orphan drug status from the FDA.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InducersProducts: PREVYMİS 240 MG İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 1 ADET, PREVYMIS 240 MG SOLUCIÓN INYECTABLENortriptyline
go.drugbank.com/drugs/DB00540ApprovedInvestigationalNortriptyline hydrochloride, the active metabolite of [amitriptyline], is a tricyclic antidepressant (TCA).
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesSynonyms: 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine, 10,11-dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-Δ5,γ-propylamineBuprenorphine
go.drugbank.com/drugs/DB00921ApprovedIllicitInvestigationalVet approved[A186263,A186266,A186269] Buprenorphine acts as a partial mu-opioid receptor agonist with a high affinity for the receptor, but lower intrinsic activity compared to other full mu-opioid agonists such … Buprenorphine is a weak partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist used for the treatment of severe pain.
Synonyms: 2-(N-cyclopropylmethyl-4,5α-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6α-yl)-3,3-dimethyl-2-butanol, 2-[3-cyclopropylmethyl-11-hydroxy-15-methoxy-(14R)-13-oxa-3-azahexacyclo[13.2.2.12,8.01,6.06,14.07,12]icosa-7,9,11-trien-16-yl]-3,3-dimethyl-2-butanolMixtures: SUBOXONE 8 MG/2 MG DILALTI TABLET, 7 ADET, Suboxone 8 mg/2 mg sublingual tabletsPosaconazole
go.drugbank.com/drugs/DB01263ApprovedInvestigationalVet approvedPosaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsProducts: POSACONAZOLO EG, POSACONAZOLO EG STADALoratadine
go.drugbank.com/drugs/DB00455ApprovedInvestigationalLoratadine is a second generation antihistamine used to manage symptoms of allergic rhinitis. … [A176435] A lack of sedative and CNS adverse effects make loratadine, along with other second generation antihistamines, preferable over their 1st generation counterparts in many clinical situations.
Mixtures: Clarinase 5 mg/ 120 mg Retardtabletten, LORATADINA+ PSEUDOEFEDRINA0.5 MG + 6 MG/ML SOLUCION PEDIATRICACategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesCertolizumab pegol
go.drugbank.com/drugs/DB08904ApprovedInvestigational[A176585] It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. … [A176606] It was developed and manufactured by UCB Pharma, first FDA approved in 2008[L45018] and updated for a new indication on March 28, 2019.[L5819]
Products: CIMZIA 200 MG, CIMZIA 200 MG ILO IN FERLovastatin
go.drugbank.com/drugs/DB00227ApprovedInvestigationalwere found in clinical studies to result in a 45.8% to 54.6% decrease in LDL cholesterol levels, while lovastatin has been found to have an average decrease in LDL-C of 25-40%. … [A174553] More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase,[A181421] which catalyzes the conversion of HMG-CoA to mevalonic acid
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSynonyms: (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(2R,4R)-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl (S)-2-methyl-butyrate, 2β,6α-dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactoneQuinidine
go.drugbank.com/drugs/DB00908ApprovedQuinidine is a D-isomer of [quinine] present in the bark of the Cinchona tree and similar plant species. … A phenomenon known as “quinidine syncope” was first described in the 1950s, characterized by syncopal attacks and ventricular fibrillation in patients treated with this drug.
Synonyms: (R)-(6-Methoxyquinolin-4-yl)((3S,4R,7S)-3-vinylquinuclidin-7-yl)methanol, (S)-(6-Methoxyquinolin-4-yl)((2R,5R)-5-vinylquinuclidin-2-yl)methanolCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InducersTadalafil
go.drugbank.com/drugs/DB00820ApprovedInvestigational[L39100, L39105] It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. … Tadalafil is a selective phosphodiesterase-5 inhibitor that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), and benign prostatic hypertrophy.
Mixtures: TADA PLUS 30/20 MG FILM KAPLI TABLET ,4 ADET, TADA PLUS 30/20 MG FILM KAPLI TABLET ,8 ADETCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates